Acasti Pharma Files 8-K
Ticker: GRCE · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Acasti Pharma INC. (GRCE) |
| Form Type | 8-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: ACST
TL;DR
ACST filed an 8-K on 10/25/24, likely with financial updates.
AI Summary
Acasti Pharma Inc. filed an 8-K on October 25, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.
Why It Matters
This filing indicates Acasti Pharma Inc. is providing updates to the SEC, which could include significant corporate events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural update and does not contain information that inherently increases risk.
Key Players & Entities
- Acasti Pharma Inc. (company) — Registrant
- October 25, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-35776 (filing_id) — SEC File Number
- 98-1359336 (tax_id) — IRS Employer Identification No.
- 103 Carnegie Center Suite 300 Princeton, New Jersey 08540 (address) — Principal Executive Offices
- ( 609 ) 322-1602 (phone_number) — Registrant's telephone number
FAQ
What specific events are being reported in this 8-K filing by Acasti Pharma Inc.?
The provided text indicates the filing is for 'Other Events' and 'Financial Statements and Exhibits' but does not specify the details of these events.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated October 25, 2024.
What is the principal executive office address for Acasti Pharma Inc.?
The principal executive offices are located at 103 Carnegie Center Suite 300, Princeton, New Jersey 08540.
Under which section of the Securities Exchange Act of 1934 is Acasti Pharma Inc. filing this report?
Acasti Pharma Inc. is filing this report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SEC file number for Acasti Pharma Inc.?
The SEC file number for Acasti Pharma Inc. is 001-35776.
Filing Stats: 461 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-10-25 08:13:49
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ACST The Nasdaq Stock Mar
Filing Documents
- ef20037632_8k.htm (8-K) — 28KB
- ef20037632_ex99-1.htm (EX-99.1) — 19KB
- image00001.jpg (GRAPHIC) — 2KB
- 0001140361-24-044212.txt ( ) — 191KB
- acst-20241025.xsd (EX-101.SCH) — 4KB
- acst-20241025_lab.xml (EX-101.LAB) — 21KB
- acst-20241025_pre.xml (EX-101.PRE) — 16KB
- ef20037632_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On October 25, 2024, Acasti Pharma Inc. (the "Company") announced via press release that it will change its corporate name to "Grace Therapeutics, Inc." effective on October 28, 2024 and its common stock will begin trading under the trading symbol "GRCE" beginning at the open of the market on October 28, 2024. The Company also announced its plans to hold a virtual Key Opinion Leader Event on November 20, 2024. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated October 25, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACASTI PHARMA INC. Date: October 25, 2024 By: /s/ Prashant Kohli Prashant Kohli Chief Executive Officer